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A total of 63 myeloproliferative neoplasms [MPN; 9 polycythemia vera (PV), 32 essential
thrombocythemia (ET), and 22 myelofibrosis (MF)] underwent spleen stiffness (SS)
measurement by vibration-controlled transient elastography equipped with a novel
spleen-dedicated module. Higher SS values significantly correlated with grade 2-3
bone marrow (BM) fibrosis (p=0.035), with hemoglobin level <10 g/dl (p=0.014) and
with white blood cells ≥10,000/ml (p=0.008). Median SS was significantly higher in MF
patients compared to ET and PV (p=0.015). SS also correlated with higher JAK2 variant
allele frequency (p=0.02). This study identifies SS as a potential noninvasive tool that
reflects BM fibrosis and the mutational burden in MPN.
Keywords: myeloproliferative neoplasms, spleen stiffness, JAK2 mutations, vibration-controlled transient
elastography (VCTE), NGSINTRODUCTION
Spleen stiffness (SS) assessment by vibration-controlled transient elastography (VCTE) has emerged as a
promisingnoninvasive toolwith gooddiagnostic accuracy for predicting the degree of portal hypertension
in patients with advanced chronic liver disease (1–5). Recently, SS and liver stiffness (LS) measurements
have been investigated also in patientswithBCR-ABL1negativemyeloproliferative neoplasms (MPNs), in
which the spleen plays an active role (5, 6). Since SS has been shown to correlate with bonemarrow (BM)
fibrosis in patients with primary myelofibrosis (MF), it has been proposed that SS measured by VCTE
might be used as a surrogate marker for BM fibrosis and as a predictor of clinical prognosis (5, 6).
However, these reports of SS assessment in MPNs have been conducted with a Fibroscan®
instrument that was not equipped with a spleen-dedicated module, which is now available and has
higher accuracy than the liver-dedicated module (7, 8). Evidence was restricted to MF and did not
include other BCR-ABL1 negative MPNs [i.e., polycythemia vera (PV) and essential
thrombocythemia (ET)] that are also characterized by BM fibrosis, albeit at a lower grade (9, 10).
Also, the correlation between SS and JAK2 or CALR mutations was analyzed only with a qualitative
assay that failed to detect a correlation (6).October 2021 | Volume 11 | Article 7777301
Moia et al. Spleen Stiffness in Myeloproliferative NeoplasmsIn this study, we aimed at evaluating SS in patients affected by
BCR-ABL1 negative MPNs by using the new Fibroscan® 630
Expert instrument equipped with a spleen-dedicated module to
assess in a more accurate manner whether SS has a potential role
in predicting BM fibrosis, in correlation with quantitative
mutational disease burden and disease severity.METHODS
Patients and Samples
Consecutive BCR-ABL1 negative MPN patients diagnosed
according to the World Health Organization (WHO) criteria
(9) followed at the Division of Haematology of Università del
Piemonte Orientale between September 15 and October 15, 2020
were included in this cross-sectional study. All patients had BM
biopsy performed at diagnosis and were provided with tumor
genomic DNA (gDNA) isolated from peripheral blood (PB) and/
or BM aspirates. SS was also evaluated in 45 healthy volunteers.VCTE Examination
Vibration-controlled transient elastography (VCTE) examinations
for liver stiffness (LS) and spleen stiffness (SS) measurements were
assessed using the instrument FibroScan® 630 Expert (Echosens,
Paris, France), equipped with liver (LSM@50Hz) and spleen
dedicated (SSM@100Hz) modules coupled with an ultrasound
localization system for the spleen. Results were expressed as kPa.
LS and SS examinations were considered reliable only if at least 10
successful measurements were obtained, the success rate was at least
60%, and the interquartile range-to-median ratio (IQR/median)
was ≤0.3. LS and SS measurements were performed by placing the
patient in a supine position with the right and left arm, respectively,
in maximum abduction and by placing the transducer in the right
and left intercostal spaces, respectively. For SS measurement, the tip
of the probe transducer was placed in a previously ultrasound
targeted point in which the spleen parenchyma had been previously
identified. LS and SS were assessed by two experienced operators. SS
was also evaluated in 45 healthy volunteers using the FibroScan®
630 Expert instrument.
Mutational Analysis
gDNA isolated from PB or BM aspirates was analyzed for JAK2,
CALR, and MPL by allele-specific PCR or by Sanger sequencing.
gDNA was also subjected to next-generation sequencing (NGS)
using the 54-gene TruSight Myeloid Sequencing Panel that
provides allelic tumor burden of the mutations that are
identified (Supplementary Appendix).Statistical Analysis
The Mann–Whitney test and the Pearson’s chi-squared test were
used to compare clinical characteristics and gene mutations with
spleen stiffness. Correlations between variables have been
performed with Spearman’s rank correlation test. Statistical
significance was defined as p value <0.05. Statistical analysis
was performed using SPSS v.24.0.Frontiers in Oncology | www.frontiersin.org 2RESULTS
A total of 65 BCR-ABL1 negative MPN patients underwent
VCTE for the measurement of LS and SS. Measurement of SS
was successful in 63/65 (97%) patients with a technique failure
rate of only 3%. Median time for examination was 50 s (IQR 35–
80). Among the 63 patients included in the study, the median age
was 72 years (IQR 58–80), and 9 (14.3%) had a diagnosis of PV,
32 (50.8%) of ET, and 22 (34.9%) of MF. Among the 22 patients
with MF, 5 patients had a previous history of ET and 6 a previous
history of PV. The median hemoglobin level was 13.2 g/dl (IQR
11.8–14.3), the median white blood count was 6.5 x 103/ml (IQR
4.8–9.2), and the median platelet count was 331 x 103/ml
(IQR 221–456). Splenomegaly, defined as a spleen longitudinal
diameter higher than 12.5 cm, was present in 28 (44.4%) patients
and, as expected, was more frequent in MF (72.7%) compared to
PV and ET (29.3%) (p=0.001). Overall, 48 patients (76.2%)
harbored JAK2 mutations, 6 patients (9.5%) CALR mutations,
and none had MPL mutations. Four (6.3%) patients were triple
negative. The complete clinical and biological characteristics are
reported in Table 1.
The median SS was 26.3 kPa (IQR 22.3–33.6), and the median
LS was 5.7 kPa (IQR 4.5–7.2). LS significantly correlated with SS
(r=0.38, p=0.002) and body mass index (BMI) (r=0.40, p=0.001),
but not with age, spleen longitudinal diameter, and BM fibrosis.
SS correlated with BM fibrosis (r=0.36, p=0.005) and spleen
longitudinal diameter (r=0.39, p=0.04), but not with BMI and
age. Two PV patients with concomitant liver cirrhosis had the
highest LS (39.0 and 14.5 kPa) and the highest SS (71.3 and 76.5
kPa) values in the cohort. In the 45 healthy volunteers, the
median SS was 16.6 kPa (range 7.3–20.9 kPa).
By comparing SS across different MPN patients, SS was
significantly higher in MF patients compared to ET and PV
patients (p=0.015). More precisely, the median SS was
significantly higher in MF (28.8 kPa; IQR 25.6–36.3) compared
to ET (24.3 kPa; IQR 21.1–28.4) (p=0.01) (Figure 1A). No
significant differences in the median SS were identified by
comparing PV (27.9 kPa, IQR 22.0–33.3) vs ET (24.3 kPa, IQR
21.1–28.4) (p=0.313), and by comparing PV (27.9 kPa, IQR 22.0–
33.3) vs MF (28.8 kPa, IQR 25.6–36.3) (p=0.317) (Figure 1A).
Whereas the value of SS differed across MPN types, no
differences in LS were observed among the three MPN
subtypes analyzed. Even after excluding from the analysis the
two PV patients with liver cirrhosis, all results for LS and SS
assessment were superimposable across MPN subtypes.
The values of SS were then correlated with the major clinical
variables of MPN. By stratifying all patients according to BM
fibrosis, the median SS was significantly higher in those with
grade 2-3 BM fibrosis compared to those with grade 0-1 fibrosis
(28.7 kPa vs. 25.0 kPa, respectively; p=0.035) (Figure 1B).
Conversely, LS did not significantly differ between patients
with a higher or lower grade of BM fibrosis (p=0.842). In
addition, SS significantly correlated with a lower hemoglobin
level. In fact, the median SS value was 31.5 kPa (IQR 28.7–39.1)
in patients with Hb <10 g/dl vs 25.4 kPa (IQR 21.7–32.8) in
patients with Hb >10 g/dl (p=0.014) (Figure 1C). Also, SS
significantly correlated with a higher WBC count, with aOctober 2021 | Volume 11 | Article 777730
Moia et al. Spleen Stiffness in Myeloproliferative Neoplasmsmedian SS of 33.5 kPa (IQR 27.5–41.7) for patients with WBC
≥10,000/ml vs 25.5 kPa (IQR 21.5–30.0) for patients with WBC <
10,000/ml (p=0.008) (Figure 1D).
A total of 51 patients underwent NGS analysis targeting 54
genes that are recurrently mutated in myeloid neoplasms. The
median variant allele frequency (VAF) of JAK2 was 22.9%. As
expected, patients with a JAK2 VAF above median (22.9%) had a
significantly higher grade of BM fibrosis (p=0.003) compared to
patients with a level of JAK2VAF below the median value. On these
grounds, we proceeded to correlate the value of quantitative JAK2
VAF with SS. Patients with JAK2 VAF above the median value had
a significantly higher SS (28.2 kPa; IQR 23.2–45.6) compared to
patients with JAK2 VAF below the median value (24.6 kPa; IQR
21.0–28.7) (p=0.027) (Figure 1E). Among the other nondriver
genes analyzed by NGS, TET2 mutated patients (3/51; 5.9%)
showed a trend toward a higher SS compared to TET2 wild-type
patients (38.0 kPa vs. 25.2 kPa, respectively; p=0.118). At variance
with NGS that provides a quantitative assessment of the mutational
burden, a simple qualitative mutation assay by allele-specific PCR
or by Sanger sequencing did not allow to identify correlations
between JAK2 (p=0.333) and CALR (p=0.692) mutations with SS.DISCUSSION
In the present study, the employment of the novel FibroScan®
630 Expert (Echosens, Paris, France), equipped with liver (LSM@
50Hz) and spleen dedicated (SSM@100Hz) modules coupled
with an ultrasound localization system for the spleen, allowed us
to evaluate spleen stiffness in patients with MPN neoplasms in aFrontiers in Oncology | www.frontiersin.org 3user-friendly manner and to identify potential correlations with
clinical and biological prognostic markers of MPNs.
Previous studies that aimed at evaluating SS in MPN patients
were performed without a spleen-dedicated module leading to a
successful rate of SS measurement of only 80% (5, 6). Because the
spleen is physiologically stiffer than the liver, previous VCTE
investigations with a liver-dedicated probe, rather than with a
spleen-dedicated probe, led to overestimating the spleen stiffness
(7, 8). To overcome these hurdles, a novel spleen-dedicated
module based on VCTE has been recently developed (7, 8). In
the present study, the successful rate of SS measurement was 97%
suggesting that SS measurement with the spleen-dedicated
module can overcome technical hurdles and represents a more
accurate and reproducible tool to evaluate SS in MPN patients.
Previous reports describing the potential value of SS
measurement in MPNs was mainly focused on MF (5, 6). In this
study, which also included PV and ET, SS values did not overlap
among the different MPN subtypes. Interestingly, MF patients
harbored a high rate of SS compared to PV and ET suggesting
that fibrotic stimuli in MF can involve different hematopoietic
tissues including the spleen. We also subsequently evaluated the
potential correlationbetweenSSanddifferent clinical andbiological
variables. Higher levels of SS correlated with a lower hemoglobin
level, a lower platelet count, and higher WBC counts pointing to a
more aggressive disease in patients with higher levels of SS. In our
study, the median SS in 45 healthy volunteers was lower than the
one measured in BCR-ABL1 negative MPN patients. These results
are consistent with a previous report of SS measured in a group of
100 healthy volunteers with point shear wave elastography. In this
group, themeanvalueof spleen stiffnesswas 18.14 (±3.08) kPa, andTABLE 1 | Patients characteristics.
Characteristics PV N=9 ET N=32 MF N=22 Total N=63
Age (years) 80 (64–85) 72 (58–81) 69 (59–76) 72 (58–80)
Gender (No.)
Female 3 (33.3%) 16 (50.0%) 11 (50.0%) 30 (47.6%)
Male 6 (66.7%) 16 (50.0%) 11 (50.0%) 33 (52.4%)
Arterial hypertension (No.) 4 (44.4%) 16 (50.0%) 9 (40.9%) 29 (46.0%)
BMI (kg/m2) 28.4 (23.3–30.3) 25.2 (23.2–28.4) 24.0 (21.9–28.8) 24.8 (22.4–28.6)
Disease duration (years) 2 (1–8) 8 (3–13) 8 (4–18) 8 (3–13)
Hb level (g/dl) 13.3 (12.5–14.1) 13.5 (12.2–14.6) 12.7 (9.9–14.1) 13.2 (11.8–14.3)
WBC (x103/µl) 6.5 (5.3–9.6) 6.1 (4.7–7.7) 7.1 (4.2–14.1) 6.5 (4.8–9.2)
PLT count (x103/µl) 296 (226–374) 367 (262–535) 256 (122–378) 331 (221–456)
Spleen LD >12.5 cm (No.) 5 (55.6%) 7 (21.9%) 16 (72.7%) 28 (44.4%)
Cirrhosis (No.) 1 (11.1%) 0 (0%) 1 (4.5%) 2 (3.2%)
Driver gene mutation (No.)
JAK2 9 (100%) 23 (71.8%) 16 (72.6%) 48 (76.2%)
CALR 0 (0%) 2 (6.3%) 4 (18.2%) 6 (9.5%)
MPL 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Triple negative 0 (0%) 3 (9.4%) 1 (4.6%) 4 (6.3%)
Liver stiffness (kPa) 6.5 (5.8–7.2) 5.0 (4.0–6.0) 5.8 (4.0–6.3) 5.7 (4.5–7.2)
Spleen stiffness (kPa) 27.9 (22.0–33.3) 24.3 (21.1–28.4) 28.8 (25.6–36.3) 26.3 (22.3–33.6)
Bone marrow fibrosis (No.)
Grade 0-1 8 (88.9%) 32 (100%) 10* (45.5%) 50 (79.4%)
Grade 2-3 0 (0%) 0 (0%) 12 (54.5%) 12 (19.0%)October 2021 | Volume 11PV, polycythemia vera; ET, essential thrombocytopenia; MF, primary myelofibrosis; No., number; BMI, body mass index; Hb, hemoglobin; WBC, white blood cells; PLT, platelets; LD,
longitudinal diameter. Continuous variables are shown as medians with the interquartile range (IQR) in the round brackets. Categorical variables are shown as numbers (No.) with the % in
the round brackets. *Include prefibrotic primary myelofibrosis.| Article 777730
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weight, and BMI (11).
MPN driver gene mutations represent an essential molecular
marker inMPNdiagnosis and prognosis, but their correlation with
SS is not completely understood. By using Sanger sequencing or
allele-specific PCR techniques, no correlations were found between
the presence of JAK2, CALR, or MPL mutations with SS. This
finding, assessedbyqualitativemolecular analysis, is consistentwith
what has been already reported inMFpatients (6). However, allele-
specific PCR and Sanger sequencing give dichotomous results and
do not dissect the allele burden of gene mutations. Conversely,
quantitative analysis defining the JAK2VAF identified a significant
association of JAK2 VAF with higher SS and, as expected, with
higher levels of BM fibrosis. This finding reinforces the notion that
JAK2 allele burden correlates with a more aggressive disease
characterized by a higher level of fibrosis not restricted to the BM
but involving also the spleen (12).
In conclusion, since SS examination correlates with the degree
of BM fibrosis and of JAK2 allele burden, SS VCTE may provide
a novel noninvasive and user-friendly assay complementing the
analysis of histological and molecular biomarkers. Given theFrontiers in Oncology | www.frontiersin.org 4noninvasive nature of SS VCTE examination, this assay may be
repeated multiple times in the individual patient, prompting
longitudinal studies in larger cohorts aimed at defining the role
of SS in prognostic models and in the long-term follow-up
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FIGURE 1 | Boxplots showing different SS values stratified according to diagnosis and clinical/molecular variables. (A) The panel shows the SS values among the
different MPNs (PV in green, ET in yellow, and MF in light blue). p values are reported above the boxplots. (B) The panel shows the difference in SS values between
patients with grade 0-1 (in green) vs grade 2-3 (in yellow) BM fibrosis. p value is reported in the right upper corner of the panel. (C) The panel shows the difference in
SS values between patients with Hb level <10 g/dl (in green) and patients with Hb level ≥10 g/dl (in yellow). p value is reported in the right upper corner of the panel.
(D) The panel shows the difference in SS values between patients with WBC ≥10,000/ml (in green) and patients with WBC <10,000/ml (in yellow). p value is reported
in the right upper corner of the panel. (E) The panel shows the difference in SS values between patients with JAK2 VAF below the median value (in green) and
patients with JAK2 VAF above the median value (in yellow). p value is reported in the right upper corner of the panel.October 2021 | Volume 11 | Article 777730
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